Emerging strategies to target RAS signaling in human cancer therapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34301278/

RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant transformation and exhibit malignant phenotypes. The mutational status of RAS correlates with the clinicopath ...